Role of Cytogenetic Evaluation in Diagnosis of Acute Myeloid Leukemia
American Journal of Biomedical and Life Sciences
Volume 4, Issue 6, December 2016, Pages: 98-102
Received: Sep. 21, 2016; Accepted: Nov. 11, 2016; Published: Dec. 14, 2016
Views 3354      Downloads 144
Authors
Gadhia Pankaj K., Cytogenetic Unit, S. N. Gene Laboratory and Research Centre, Surat, India
Patel Monika V., Cytogenetic Unit, S. N. Gene Laboratory and Research Centre, Surat, India
Vaniawala Salil N., Cytogenetic Unit, S. N. Gene Laboratory and Research Centre, Surat, India
Article Tools
Follow on us
Abstract
Aim: Acute leukaemia represents clonal haematological disorders that arise from at least two or more genetics alteration in susceptible haematological cells. The cytogenetic study confirms a wide variety of common, rare and novel chromosomal anomalies in patients with haematological disorders providing valuable diagnostics and prognostic information. Method: Cytogenetic analyses were carried out in a total 4600 suspected patients. Of which, 68 patients were reported with Acute Myeloid Leukaemia. Cytogenetic analyses from bone marrow cultures having age ranging from 5 years to 65 years were carried out. GTG banded metaphases were analysed and karyotypes by automatic karyotyping system and confirmation were made by using Florescent In Situ Hybridization technique (FISH). Results: Results revealed that out of 68 AML patients only 36 patients (52.9%) were found with translocation t(8; 21) (q22; q22) in AML-M2 subtype, 23 patients (33.8%) were found with a translocation t(15; 17) (q22; q12) in AML-M3 and only 09 patients(13.2%) were found with inversion in chromosome16 inv(16) (p13; q22) in AML-M4. Conclusion: It is concluded from the present study that a high prevalence rate of AML were found in t(8; 21) (q22; q22) followed by t(15; 17) (q22; q12) and inv(16) (p13; q22). The significance of results is discussed.
Keywords
G-banding, Karyotype, AML, FISH
To cite this article
Gadhia Pankaj K., Patel Monika V., Vaniawala Salil N., Role of Cytogenetic Evaluation in Diagnosis of Acute Myeloid Leukemia, American Journal of Biomedical and Life Sciences. Vol. 4, No. 6, 2016, pp. 98-102. doi: 10.11648/j.ajbls.20160406.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
SL. Starza, C. Matteucci, B. Crescenzi, G. Perla, M. Carotenuto, MF. Martelli et al., “Identification of chromosome changes in Acute myeloid leukemia (AML-L2) by Molecular cytogenetics” Can Genet Cytogenet, 1997, 95, pp. 148-152.
[2]
S Yohe, “ Molecular Genetic markers in Acute leukemia”. J. Clin. Med., 2015, 4: pp. 460-478.
[3]
S. Frohling, RF. Schlenk, J. Breitruck, A. Benner, KS. Tobis, H. Dohner and K. Dohner, “Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of AML study Group Ulm”, Blood, 2002, 100: pp. 4372-4380.
[4]
O. Blau, R. Berenstein, A. Sindram, IW. Blau. “Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia”. Leuk. Lymphoma 2013, 54, pp. 145–152.
[5]
TL. Lin, T. Williams, J. He, OS. Aljitawi, S. Ganguly, S. Abhyankar, S. Fleming, H. Male and JP. McGuirk, “Rates of complete diagnostic testing for patients with acute myeloid leukemia” Cancer Mdicine, 2015, 4(4): pp. 519-522.
[6]
ED. Velloso, CH, Motta, JB. Furtado, NS. Bacal, PA. Silveira, CB. Moyses, R. Sitnik, and JR. Pinho, “Molecular and cytogenetic abnormalities in acute myeloid leukemia: Review and case studies”, Einstein, 2011, 9(2), pp. 184-189.
[7]
F. Ahmed, P. Kokte, P. Chedda, R. Dalvi, B. Ranjandas and S. Mandava, “Molecular cytogenetic findings in a three-way novel variant of t(1; 8; 21) (p35; q22; q22) a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2”, Cancer Genet. Cytogenet., 2008, 180: pp. 153-157.
[8]
ISCN, International System for Human Cytogenetics Nomenclature (ISCN), 2009, S. Karger Publ. Inc.
[9]
RM, Stone, MR, O’Donnell, MA, Sekeers, “Acute myeloid leukemia”, Am. Soc. Hematol. Edu. Program, 2004, pp. 98-117.
[10]
B, Williams, A, Amon, (2009). Aneuploidy: Cancer's Fatal Flaw?. Cancer Research, 69(13), pp. 5289-5291.
[11]
D, Grimwade, RK, Hills, AV, Moorman, H, Walker S, Chatters, AH, Goldstone, AK, Burnett, “Refinement of cytogenetic classification in acute myeloid leukaemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council Trials” Blood, 116(3), pp 354-365.
[12]
C. Chandra Kumar, “Genetic abnormality and challenges in the treatment of Acute myeloid leukemia”, Gene and Cancer, 2011, 2(2): pp. 95-107.
[13]
MLLF. Chauffaile, MS. Figueiredo, R. Beltrani, R. Antunes, SV. Yamomoto and J. Kerbauy, “Acute promyelocytic leukemia: the study of t(15; 17) transloction by fluorescent in situ hybridization, reverse trancriptase polymerase chain reaction and cytogenetic techniques” Brazilian J. Medical and Biological Research, 2001, 34: pp. 735-743.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186